<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087190</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0009</org_study_id>
    <nct_id>NCT01087190</nct_id>
  </id_info>
  <brief_title>Isoniazid (INH) Treatment Based on ELISPOT Assay</brief_title>
  <official_title>A Prospective, Randomized, Open Labeled Trial of Isoniazid Treatment Based on ELISPOT Assay to Prevent Tuberculosis in a Kidney Transplant Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been recommended that all transplant recipients undergo a tuberculin skin test (TST)&#xD;
      before transplantation. However, the ability of TST to diagnose latent tuberculosis infection&#xD;
      (LTBI) in transplant candidates has been reported to be suboptimal because of high rates of&#xD;
      false-negative and false-positive results. The enzyme-linked immunospot assay (ELISPOT)&#xD;
      detecting interferon-gamma secreting T-cells for diagnosing tuberculosis infection gave&#xD;
      promising results in immunocompromised patients as well as in immunocompetent patients. The&#xD;
      investigators will perform a randomized, open-label, prospective trial of isoniazid (INH)&#xD;
      prophylaxis based on ELISPOT assay for LTBI in renal transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous data have shown that ELISPOT assay was more sensitive to detect LTBI in renal&#xD;
      transplant recipients than TST (Kim SH, et al. Transplant Infect Dis 2010 Jan 25 [Epub ahead&#xD;
      of print]). However, further studies are eagerly awaited to determine the efficacy of&#xD;
      isoniazid (INH) prophylaxis based on ELISPOT assay for LTBI in renal transplant recipients.&#xD;
      All adult patients admitted for renal transplantation between May 2010 and April 2013 at the&#xD;
      Asan Medical Center, Seoul, South Korea, will be prospectively enrolled. INH (300 mg/day for&#xD;
      9 months) prophylaxis group and no prophylaxis group (control group) will be randomly&#xD;
      assigned to all patients with a baseline positive ELISPOT assay regardless of the results of&#xD;
      TST. The investigators will compare cumulative probability of developing active TB after&#xD;
      transplantation between INH prophylaxis group and control group as primary outcome. Secondary&#xD;
      outcomes will be adverse drug reactions, rejection episodes, graft survival, and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of tuberculosis (the rate of tuberculosis after transplantation)</measure>
    <time_frame>3 years</time_frame>
    <description>Confirmed tuberculosis Probable tuberculosis Suspected or possible tuberculosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause deaths</measure>
    <time_frame>3 years</time_frame>
    <description>TB-associated deaths&#xD;
non-TB-associated deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INH-associated adverse drug reactions</measure>
    <time_frame>3 years</time_frame>
    <description>liver function abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">831</enrollment>
  <condition>Kidney Transplant Recipient</condition>
  <arm_group>
    <arm_group_label>INH treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)&#xD;
INH 300 mg po qd for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>randomly allocated to control group in renal transplant recipients with ELISPOT (+)&#xD;
no treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>allocated to observation group in renal transplant recipients with ELISPOT (-)&#xD;
no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid treatment</intervention_name>
    <description>isoniazid 300 mg po qd for 9 months</description>
    <arm_group_label>INH treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  16 years or more&#xD;
&#xD;
          -  Kidney transplant recipients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not receive isoniazid treatment due to abnormal liver function (i.e.&#xD;
             Child-Pugh Score B or C)&#xD;
&#xD;
          -  Patients who have clinical risk factors for latent tuberculosis infection&#xD;
&#xD;
               1. Close contact with a person with pulmonary TB within the past year&#xD;
&#xD;
               2. Abnormal chest radiography and no prior prophylaxis&#xD;
&#xD;
               3. A history of untreated or inadequately treated TB&#xD;
&#xD;
               4. New infection (i.e. a recent conversion of TST to positive status)&#xD;
&#xD;
                    -  If kidney transplant donor has these clinical risk factors for latent&#xD;
                       tuberculosis infection, the transplant recipient from this donor will be&#xD;
                       excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Han Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>kidney</keyword>
  <keyword>transplantation</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>ELISPOT</keyword>
  <keyword>isoniazid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

